Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fadraciclib in Advanced Solid Tumors and Lymphoma
NCT04983810Phase 2Recruiting
- Sponsor
- Cyclacel Pharmaceuticals, Inc.
- Start
- Jul 2021
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of fadraciclib in solid tumor (advanced stage), lymphoma, endometrial cancer (EC) and 7 more, sponsored by Cyclacel Pharmaceuticals, Inc. Primary endpoints: Maximum Tolerated Dose at 6 months and Overall Response Rate at 18 months. Started Jul 2021; status: recruiting.
02
Drugs
fadraciclib
03
Conditions
solid tumor (advanced stage)lymphomaendometrial cancer (EC)ovarian cancerbiliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT04983810.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04983810.